Brigatinib from Ariad and Takeda, also an inhibitor of mutated EGFR, was the latest second-generation ALK inhibitor approved in 2017 by the US FDA for ALK(+) NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.